跳至主要内容

Hemolysis Assay Labs

 

Hemolysis Assay

The hemolysis assay is used to determine the hemolytic effect of a test compound.


Hemolytic activity is a requirement to be tested for any blood contacting medical device. The test is based on erythrocyte lysis induced by contact, leachables, toxins, metal ions, surface charge or any other cause of erythrocyte lysis. The current description is based on direct contact of biomaterial and an erythrocyte suspension. The method is based on release of hemoglobin, which can be measured spectrophotometrically. This method is suited to evaluate the hemocompatibility of biomaterials and medical devices according to the international standard ISO 10993-4:2002.

The Hemolysis test is designed to determine the hemolytic properties of a medical device/material. This test is performed on medical devices/materials that have direct or indirect blood contact.

  • Evaluate your small molecule, biologic, or formulation excipients for its potential to lyse red blood cells
  • Personalized experimental design to ensure the most relevant data is obtained with the options to examine all relevant in vivo pharmacologically relevant blood from appropriate species
  • All assays are performed with high-quality reagents and strict controls by experienced immunologists

Required from Customer

  • Either a minimum of 300 µL of test compound at 10 mM in DMSO, or 5 mg of powder
  • Molecular mass (exact mass) of the test compound and its salt form
  • MSDS and handling and storage information, e.g., light sensitive, store at -20°C, etc.

Deliverables

  • Percent of hemolysis in each sample
  • Rate of hemolysis, if applicable

Substrate

  • Test compound dissolved in DMSO applied to a suspension of red blood cells in isotonic buffer or plasma. The final dosing concentration is typically 10 uM or the clinical Cmax

Assay System

  • A suspension of red blood cells from a species specified by the customer
  • The positive control: red blood cells treated with 0.1% SDS (sodium dodecyl sulfate) to produce 100% hemolysis
  • The negative control: red blood cells treated with DMSO

Hemolysis Assay Conditions

  • Prepare three separate test tubes (N=3) containing red blood cells dosed with the test compound dissolved in DMSO
  • Incubated at 37°C in a water bath with mild agitation
  • Sample each replicate at 0, 5, 15, 30, 60, 120 and 180 minutes
  • Centrifuge each sample
  • Measure the absorbance of the supernatant from each sample using a UV/Vis spectrometer
  • Calculate percent hemolysis at each sampling time point

Hemolysis Assay Dynamic Range

  •  Hemolysis can be determined from between 10 and 100% with a typical precision (N=3) of 10%

Hemolysis Assay QC

  • Positive and negative controls run with each compound

Options

The customer may select:

  • either the basic, standard or custom report format
  • the species of blood donor plasma or isotonic buffer

The customer can request:

  • additional replicates
  • the use of a control buffer in which the stability of the test compound is measured
  • the concentration of the test compound


Contact Us:
Email : marketing@medicilon.com
Tel : +86 021 58591500
Website: https://www.medicilon.com

标签：

评论

发表评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou
发表评论
阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d
发表评论
阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati
发表评论
阅读全文